Fox Chase’s Cihangir Duy Receives an American Society of Hematology 2023 Scholar Award

Cihangir Duy, PhD, MS, an assistant professor in the Nuclear Dynamics and Cancer research program and a member of the Cancer Epigenetics Institute at Fox Chase Cancer Center, has been awarded an American Society of Hematology (ASH) 2023 Junior Faculty Scholar Award in basic/translational research.

“I’m very grateful to ASH for this distinguished award,” said Duy. “The funding will allow us to continue in our research, which includes investigating how certain acute myeloid leukemia cells can reinitiate leukemia after chemotherapy.”

One of ASH’s most prestigious research award programs, the ASH Scholar Awards support early career investigators dedicated to careers in hematology research as they transition from training programs to careers as independent investigators.

Duy received $150,000 with the award, which funds hematologists in the United States and Canada who conduct basic, translational, and clinical research that furthers the understanding and treatment of blood disorders.

“The ASH Scholar Award provides vital recognition for emerging research scientists. The prize not only acknowledges their contributions to the field of hematology, but also provides them with the resources and support they need to continue their pioneering work,” said Robert A. Brodsky, MD, 2023 ASH president and professor of Medicine and Oncology and Director of Hematology at Johns Hopkins School of Medicine.

“For more than 35 years now, ASH has supported fellows and early career faculty who go on to make a lasting impact on hematology. We congratulate this year’s recipients and look forward to watching them transform the field and improve the care of individuals living with blood disorders,” he added.

ASH is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. ASH Scholar Awards are made possible through support from the ASH Foundation as well as from the corporate community, individual donors, and funds committed by the Society. This year’s supporters included AstraZeneca, Bristol Myers Squibb, the Deerfield Foundation, and Pharmacyclics LLC.

***

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427.